DongKoo Bio&Pharma Co. Ltd (006620) — Cash Flow Reinvestment Rate
DongKoo Bio&Pharma Co. Ltd (006620) has a Cash Flow Reinvestment Rate of 3.63x as of September 2025, reinvesting ₩4.34 Billion (capex ₩3.66 Billion plus investments ₩-676.51 Million) from operating cash flow of ₩1.20 Billion. Explore reinvestment intensity of DongKoo Bio&Pharma Co. Ltd to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
DongKoo Bio&Pharma Co. Ltd Cash Flow Reinvestment Rate (2015–2024)
Historical reinvestment intensity for DongKoo Bio&Pharma Co. Ltd across 9 annual periods. Also explore how large is DongKoo Bio&Pharma Co. Ltd's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for DongKoo Bio&Pharma Co. Ltd (2015–2024)
Year-by-year capital reinvestment analysis for DongKoo Bio&Pharma Co. Ltd. For live market cap and broader valuation context, see DongKoo Bio&Pharma Co. Ltd (006620) total market value.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 4.06x | ₩70.50 Billion | ₩17.34 Billion | ₩25.46 Billion | ▼ -30.9% |
| 2023 | 5.88x | ₩21.10 Billion | ₩3.59 Billion | ₩15.97 Billion | ▲ +159.8% |
| 2022 | 2.26x | ₩38.09 Billion | ₩16.82 Billion | ₩11.08 Billion | ▲ +287.3% |
| 2021 | 0.58x | ₩10.47 Billion | ₩17.90 Billion | ₩4.27 Billion | ▼ -61.4% |
| 2020 | 1.51x | ₩11.34 Billion | ₩7.49 Billion | ₩5.27 Billion | ▼ -24.7% |
| 2019 | 2.01x | ₩20.38 Billion | ₩10.14 Billion | ₩8.77 Billion | ▲ +972.5% |
| 2017 | 0.19x | ₩1.78 Billion | ₩9.51 Billion | ₩810.51 Million | ▼ -68.7% |
| 2016 | 0.60x | ₩7.54 Billion | ₩12.59 Billion | ₩6.55 Billion | ▲ +12.0% |
| 2015 | 0.53x | ₩3.71 Billion | ₩6.93 Billion | ₩2.32 Billion | — |